Neoplasia Chromosomal Microarray Analysis
GTR Test Accession: Help GTR000531723.4
CAP
CANCERHEMATOLOGYINHERITED DISEASE ... View more
Last updated in GTR: 2022-05-25
Last annual review date for the lab: 2024-06-24 LinkOut
At a Glance
Diagnosis; Prognostic
Acute lymphoid leukemia; Acute myeloid leukemia; B-cell chronic lymphocytic leukemia more...
Molecular Genetics - Deletion/duplication analysis: Microarray
Chromosomal SNP microarray analysis is increasingly relevant in establishing a …
Not provided
Not provided
Ordering Information
Offered by: Help
Clinical Genomics Laboratory
View lab's website
View lab's test page
Test short name: Help
Neoplasia CMA
Specimen Source: Help
Who can order: Help
  • Genetic Counselor
  • Health Care Provider
  • Licensed Physician
  • Nurse Practitioner
  • Physician Assistant
  • Registered Nurse
CPT codes: Help
**AMA CPT codes notice
Lab contact: Help
Yu Wu, PhD, Lab Supervisor
[email protected]
206-616-4062
Contact Policy: Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order: Help
Test kits with return shipping are available, as needed. Email [email protected] or call 206-598-8684 to request kits. Please see the lab's website for complete information about sample requirements, ordering and shipping, and test requisitions.
Order URL
Informed consent required: Help
No
Pre-test genetic counseling required: Help
No
Post-test genetic counseling required: Help
No
Recommended fields not provided:
Conditions Help
Total conditions: 15
Condition/Phenotype Identifier
Test Targets
Chromosomal regions/Mitochondria Help
Total chromosomal regions/mitochondria: 1
Chromosomal region/Mitochondrion Associated condition
Methodology
Total methods: 1
Method Category Help
Test method Help
Instrument
Deletion/duplication analysis
Microarray
Illumina iScan
Clinical Information
Test purpose: Help
Diagnosis; Prognostic
Target population: Help
Chromosomal SNP microarray analysis is increasingly relevant in establishing a diagnosis and prognosis for people with hematologic cancers (e.g. leukemia, ALL, AML, MDS) and solid tumors (e.g. sarcomas, renal cell carcinomas, brain tumors), because it detects abnormalities missed by the more traditional methods of karyotyping and FISH.
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS? Help
CNVs interpreted using DGV, Atlas of Genetics and Cytogenetics in Hematology and Oncology, Cosmic Catalog of Somatic Mutations in Cancer. Determination of clinical significance and reports are based on ACMG Guidelines.

Are family members with defined clinical status recruited to assess significance of VUS without charge? Help
No.

Will the lab re-contact the ordering physician if variant interpretation changes? Help
No. The ordering provider is welcome to contact lab to request an updated interpretation of any CNVs detected previously.
Recommended fields not provided:
Technical Information
Test Platform:
Illumina Infinium CytoSNP-850K BeadChip
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
As per ACMG guidelines, 30 known normal and abnormal samples were used to validate the assay. The microarray detected 100% of the abnormalities.
Assay limitations: Help
This microarray will detect aneuploidy as well as copy number gains (duplications or amplifications), copy number losses (deletions), and regions of copy number neutral loss of heterozygosity (cnLOH) for the loci represented on the microarray. Analysis in our laboratory is limited to detecting copy number changes (deletions and duplications) that … View more
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
Yes

Method used for proficiency testing: Help
Formal PT program

PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP

Description of PT method: Help
As part of CAP accreditation, proficiency testing is performed two times per year. The laboratory is provided with approximately 4 unknown specimens for testing each year, and results are returned to CAP for evaluation.
VUS:
Software used to interpret novel variations Help
DGV, Atlas of Genetics and Cytogenetics in Hematology and Oncology, Cosmic Catalog of Somatic Mutations in Cancer

Laboratory's policy on reporting novel variations Help
For neoplasia arrays, variants of uncertain clinical significance and likely constitutional variants of uncertain significance are not reported.
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Not provided
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.